Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

NCT06420440 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

HCC

Interventions

PROCEDURE: Hepatic arterial infusion chemotherapy
DRUG: Lenvatinib
DRUG: Tislelizumab
PROCEDURE: Liver resection
DRUG: Tislelizumab

Sponsor

Chen Xiaoping